Copyright
        ©The Author(s) 2015.
    
    
        World J Gastroenterol. Mar 14, 2015; 21(10): 3041-3048
Published online Mar 14, 2015. doi: 10.3748/wjg.v21.i10.3041
Published online Mar 14, 2015. doi: 10.3748/wjg.v21.i10.3041
            Table 1 Characteristics of all subjects and outcomes n (%)
        
    | PEG-Asc | 4-L PEG | P value | |
| n | 112 | 114 | |
| Age (yr, mean ± SD) | 56 ± 10 | 55 ± 12 | 0.525 | 
| Sex (male) | 54.50% | 64% | 0.143 | 
| Previous colonoscopy | 55 (49.1) | 58 (50.9) | 0.790 | 
| Complete bowel preparation | 112 (100) | 111 (97.4) | 0.247 | 
| Morning colonoscopy | 68 (60.7) | 54 (47.4) | 0.044 | 
| Indications of colonoscopy | 0.515 | ||
| Colon cancer screening | 65 (58) | 71 (62.3) | |
| Functional GI symptoms | 47 (42) | 43 (37.7) | |
| Polyp detection rate | |||
| Polyp ≥ 1 | 58 (51.8) | 53 (46.5) | 0.506 | 
| Procedure time | |||
| Insertion time (min, mean ± SD) | 5.8 ± 4.5 | 5.8 ± 3.3 | 0.938 | 
| Withdrawal time (min, mean ± SD) | 9.4 ± 5.5 | 8.4 ± 2.4 | 0.420 | 
            Table 2 Laboratory findings before and after intake of the bowel preparation solutions
        
    | PEG-Asc | 4-L PEG | P value1 | |
| Serum | |||
| Sodium | 0.161 | ||
| Before, mmol/L | 140.0 ± 2.4 | 139.8 ± 1.9 | |
| After, mmol/L | 140.8 ± 2.6a | 141.1 ± 2.1a | |
| Potassium | 0.005 | ||
| Before, mmol/L | 4.1 ± 0.3 | 4.2 ± 0.3 | |
| After, mmol/L | 4.2 ± 0.4 | 4.0 ± 0.4a | |
| Chloride | 0.259 | ||
| Before, mmol/L | 103.4 ± 3.3 | 103.2 ± 2.8 | |
| After, mmol/L | 105.3 ± 3.4a | 103.2 ± 3.1 | |
| Magnesium | 0.447 | ||
| Before, mg/dL | 2.2 ± 0.2 | 2.2 ± 0.1 | |
| After, mg/dL | 2.1 ± 0.2 | 2.1 ± 0.2 | |
| Phosphorus | 0.009 | ||
| Before, mg/dL | 3.4 ± 0.4 | 3.4 ± 0.5 | |
| After, mg/dL | 3.6 ± 0.5a | 3.4 ± 0.4 | |
| Calcium | 0.174 | ||
| Before, mg/dL | 8.9 ± 0.5 | 8.9 ± 0.9 | |
| After, mg/dL | 9.7 ± 8.1 | 9.0 ± 0.4 | |
| Urea | 0.624 | ||
| Before, mg/dL | 14.0 ± 4.7 | 13.8 ± 3.4 | |
| After, mg/dL | 13.1 ± 4.6a | 12.6 ± 3.9a | |
| Creatinine | 0.172 | ||
| Before, mg/dL | 1.0 ± 1.1 | 0.8 ± 0.2 | |
| After, mg/dL | 0.8 ± 0.2 | 0.8 ± 0.2 | |
| Serum osmolarity | 0.733 | ||
| Before, mmol/kg | 293.1 ± 31.2 | 291.6 ± 8.2 | |
| After, mmol/kg | 294.4 ± 57.8 | 291.1 ± 11.5 | |
| Urine | |||
| Urine osmolarity | 0.741 | ||
| Before, mmol/L | 633.2 ± 222.1 | 639.7 ± 212.4 | |
| After, mmol/L | 694.4 ± 216.1a | 693.8 ± 183.7a | 
            Table 3 Proportion of patients with over-changed values n (%)
        
    | PEG-Asc | 4-L PEG | P value | |
| (n = 112) | (n = 114) | ||
| Na change > 4.5 mmol/L | 7 (6.3) | 14 (12.4) | 0.113 | 
| K change > 0.8 mmol/L | 5 (4.5) | 6 (5.3) | 0.769 | 
| Ca change > 0.7 mg/dL1 | 4 (3.6) | 4 (3.5) | > 0.999 | 
| Mg change > 0.7 mg/dL1 | 2 (1.8) | 0 (0) | 0.244 | 
| P change > 0.7 mg/dL | 21 (18.8) | 16 (14.0) | 0.338 | 
| S osm change > 7.5 mmol/kg | 61 (54.5) | 51 (44.7) | 0.144 | 
| Cr change > 0.7 mg/dL | 0 (0) | 0 (0) | > 0.999 | 
            Table 4 Scores of adequacy of bowel preparation according to the Boston Bowel Preparation Scale
        
    | PEG-Asc | 4-L PEG | P value | |
| Right segment | 2.2 ± 0.8 | 2.3 ± 0.7 | 0.175 | 
| Transverse segment | 2.4 ± 0.8 | 2.4 ± 0.7 | 0.687 | 
| Left segment | 2.4 ± 0.8 | 2.5 ± 0.8 | 0.610 | 
| Total segment | 7.0 ± 2.1 | 7.1 ± 2.0 | 0.601 | 
            Table 5 Adverse events and subjective feelings n (%)
        
    | PEG-Asc | 4-L PEG | P value | |
| Adverse events | |||
| Nausea | 32 (28.6) | 34 (29.8) | 0.836 | 
| Vomiting | 7 (6.3) | 12 (10.5) | 0.247 | 
| Abdominal pain | 11 (9.8) | 10 (8.8) | 0.786 | 
| Abdominal distension | 38 (33.9) | 45 (39.5) | 0.387 | 
| Thirst | 25 (22.3) | 21 (18.4) | 0.467 | 
| Dizziness | 13 (11.6) | 7 (6.1) | 0.148 | 
| Aphtous ulcer | 2 (1.8) | 1 (0.9) | 0.620 | 
| Subjective feelings | |||
| Feel difficult | 16 (14.3) | 35 (30.7) | 0.003 | 
| Taste “good” | 46 (41.1) | 19 (16.7) | < 0.001 | 
| Willingness | 82 (73.2) | 67 (59.3) | 0.027 | 
- Citation: Lee KJ, Park HJ, Kim HS, Baik KH, Kim YS, Park SC, Seo HI. Electrolyte changes after bowel preparation for colonoscopy: A randomized controlled multicenter trial. World J Gastroenterol 2015; 21(10): 3041-3048
- URL: https://www.wjgnet.com/1007-9327/full/v21/i10/3041.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i10.3041

 
         
                         
                 
                 
                 
                 
                 
                         
                         
                        